RET and neoplasm: For example, the RET-inhibitor, pralsetinib, and the TRK inhibitors, entrectinib and larotrectinib, have recently been approved in a tumour agnostic approach, meaning that once a RET or NTRK-fusion has been identified, treatment with a RET or TRK inhibitor can be instigated regardless of tumour origin [32].